<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694016</url>
  </required_header>
  <id_info>
    <org_study_id>RIPC00AVR</org_study_id>
    <nct_id>NCT02694016</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery</brief_title>
  <official_title>Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery With a Biological Prosthesis: A Single Center Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oulu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to investigate the efficacy, safety and possible neuro- and cardioprotective
      effects of remote ischemic preconditioning (RIPC) in adult cardiac patients undergoing
      isolated aortic valve replacement surgery with a biological prosthesis. Neuropsychological
      evaluation preoperatively and at 30d after surgery will establish if there are any
      differences in neuropsychological performance between groups. A large array of biochemical
      markers will be analyzed from plasma samples taken at different time points. Additionally
      skin biopsies from the lower limb will be taken before and after performing RIPC on said
      limb. During the venous cannulation phase a atrial biopsy will be taken. The biochemical
      markers from plasma and tissue samples will be used to asses brain tissue damage,
      inflammation and cardiac tissue damage between groups.

      This will be a single center prospective randomized study with two groups. A intervention
      group (RIPC) and a control group. Study size is: 40 patients in total, 20 patients per group.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment pace
  </why_stopped>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychological assesment</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>Investigators will use a neuropsychological test battery to test our subject pre- and post-operatively. A qualified psychologist will administer the test battery. The test battery will be relatively simple but still have several different tests. These tests will include but are not limited to:
- Trail Making test A &amp; B (TMT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychological assesment</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>Digit Span test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychological assesment</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>Rey Auditory Verbal Learning Test (RAVLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation markers analysed from plasma and tissue samples</measure>
    <time_frame>A day before surgery, during surgery, 24hour and 48hour postoperatively</time_frame>
    <description>A bioplex/multiplex assay of systemic inflammatory response markers and other cytokines including but not limited to:
Tumor Necrosis Factor-a, Interleukin-1b, -2, -4, -5, -6. C-Reactive Protein, Hypoxia inducible Factor -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue specific markers analysed from plasma</measure>
    <time_frame>A day before surgery, during surgery, 24hour and 48hour postoperatively</time_frame>
    <description>A bioplex/multiplex assay of neuronal and cardiac tissue specific biomarkers including but not limited to:
S-100b, Glial Fibrillary acidic protein, Neuron Specific enolase, Troponin-I, Brain Natriuretic Peptide, Creatinine Kinase - MB</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Remote ischemic preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote ischemic preconditioning</intervention_name>
    <description>A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.</description>
    <arm_group_label>Remote ischemic preconditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-emergency aortic valve replacement with a biological prosthesis with perfusion and
             cardiac arrest

        Exclusion Criteria:

          -  Recent myocardial infarction

          -  Carotid stenosis requiring intervention

          -  Any other concomitant surgical procedure

          -  Increased troponin baseline before surgery

          -  Critical ischemia of lower limbs

          -  Peripheral arterial disease (ASO, media sclerosis)

          -  Morbid obesity (Incompatible cuff-to-thigh diameter)

          -  Severe heart insufficiency

          -  Moderate to severe venous insufficiency lower limbs

          -  Recent acute stroke &lt;90d

          -  Difference in cardioplegic protocol

          -  Diseased aorta in epiaortic ultrasound
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredrik Yannopoulos, MD Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vesa Anttila, MD Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuomas Ahvenvaara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuomas Mäkelä, MD.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oulu University Hospital, Department of Cardiothoracic surgery</name>
      <address>
        <city>Oulu</city>
        <zip>900220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oulu University Hospital</investigator_affiliation>
    <investigator_full_name>Fredrik Yannopoulos</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Remote ischemic preconditioning</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://drive.google.com/file/d/0B8f6XnAry76dUERObVRWUjhGZzg/view?usp=sharing</doc_url>
      <doc_comment>English protocol description file</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://drive.google.com/file/d/0B8f6XnAry76dYW04ZDNld3VNV2c/view?usp=sharing</doc_url>
      <doc_comment>Finnish language consent form</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Patient information in Finnish</doc_type>
      <doc_url>https://drive.google.com/file/d/0B8f6XnAry76dTGEtenRaUENSUTg/view?usp=sharing</doc_url>
      <doc_comment>Patient information in Finnish</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

